Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 1287 results for position

  1. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

    Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

  2. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  3. Policies, procedures and reports

    Policies, procedures, reports and codes of practice relating to the governance of NICE.

  4. Office for Digital Health

    The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.

  5. Sole supplied titles

    Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.

  6. Prioritising our guidance topics

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  7. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  8. Our role in the Innovative Licensing and Access Pathway (ILAP)

    The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.

  9. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  10. Hypertension in adults: diagnosis and management (NG136)

    This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

  11. Otitis media (acute): antimicrobial prescribing (NG91)

    This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

  12. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.

  13. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.